Company Analysis
Sign in

BioCardia, Inc. (BCDA)

Nasdaq: BCDA · Biological Products, (No Diagnostic Substances) · Sunnyvale, CA · filing with the SEC since 1996
Full chart Alerts Compare
Grade4.1
◀ Past 2.1● Present 4.6▶ Future 4.9
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of BioCardia, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.1/10
◀ Past2.125% of the headline
● Present4.635% of the headline
▶ Future4.940% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.1/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.7/10

Has it survived what it has been through?

13 warning events since 2017; the latest 2026-08-21.

weight 22% of this tense · 17th percentile among 159 sector filers · read for itself

From the record

BioCardia, Inc.'s filings since 2017 show 13 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 9 times, the latest 2026-08-21); an auditor change (8-K item 4.01, the latest 2020-11-13); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2020-03-31) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
2.4/10

What has it actually done, year after year?

10 filed years; profitable in 0 of 10.

weight 45% of this tense · 24th percentile among 102 sector filers · read for its customers

From the record

BioCardia, Inc.'s 10 filed years say what it did: it rose in 4 of 9 years; the deepest fall was 100% from fiscal 2022 to fiscal 2025; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

  • the share of years revenue rosebottom 31% of its family
  • the share of filed years with a profitbottom 31% of its family
  • the deepest fall from a revenue peak100.0%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
1.9/10

How has it treated the people who own it?

SI estimate 1.9/10, confidence 35 of 100 (one part).

weight 33% of this tense · 19th percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 19% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioCardia, Inc.'s shareholder treatment is put at 1.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 19% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.6/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
1.5/10

Is it financially healthy right now?

ROE -919%: lost 919¢ per shareholder dollar. Leverage 74%: owes 74¢ per asset dollar.

weight 45% of this tense · 15th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, BioCardia, Inc. lost about 919 cents for every dollar of shareholders' money. Leverage: it owed about 74 cents per dollar of assets, and net share issuance: its share count grew 143.0% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 27% of its family
  • return on equitybottom 4% of its family
  • the share count against the year beforebottom 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

SI estimate
4.9/10

How strong is its position in its industry?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 102 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
No filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 102 members with one.
What the record cannot read
No filed revenue on file.
How it was reasoned
family median, 102 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioCardia, Inc.'s industry position is put at 4.9 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 102 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Leadership

as filed
8.7/10

What are the people in charge doing?

top 13% of 110 in its family for leadership; chief executive since 2016.

weight 33% of this tense · 87th percentile among 110 sector filers · read for its shareholders

From the record

BioCardia, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Altman, Peter (President and CEO, as filed), filing under that title since 2016-10-26, 10 years (top 9% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 6.7 years (top 25%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 9 people in charge now (top 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge1 in three years among 9 peopletop 6% of its family
  • the median years the people in charge have filed6.7 yearstop 25% of its family
  • the chief executive's years on the record10.0 yearstop 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.9/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

SI estimate
7.9/10

How much room does it have to grow?

SI estimate 7.9/10, confidence 35 of 100 (one part).

weight 33% of this tense · 79th percentile among 152 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the top 21% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 152 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioCardia, Inc.'s room to expand is put at 7.9 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 21% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
2.2/10

What could actually drive growth from here?

bottom 22% of 100 in its family for growth drivers.

weight 45% of this tense · 22nd percentile among 100 sector filers · read for its customers

From the record

BioCardia, Inc.'s growth drivers, from the filed years to fiscal 2025: research spending grew -17.5% a year (bottom 17%); capital spending grew -53.6% a year (bottom 28%) (its annual reports). BioCardia, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth of research spending-17.5%bottom 17% of its family
  • three-year growth of capital spending-53.6%bottom 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
5.6/10

Did its newest year beat what its own record pointed to?

SI estimate 5.6/10, confidence 35 of 100 (one part).

weight 22% of this tense · 56th percentile among 90 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, net income against the prior three years' average, which ranks in the top 44% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: net income against the prior three years' average, the one part on file, ranked among 90 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioCardia, Inc.'s expectations vs reality is put at 5.6 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the top 44% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton BCDA · research, not advice